Literature DB >> 2703528

Lymphocyte proliferative responses to human immunodeficiency virus antigens in vitro.

J F Krowka1, D P Stites, S Jain, K S Steimer, C George-Nascimento, A Gyenes, P J Barr, H Hollander, A R Moss, J M Homsy.   

Abstract

All HIV seronegative (HIV Ab-) and most HIV seropositive (HIV Ab+) individuals' lymphocytes failed to proliferate in primary cultures in response to purified HIV or to recombinant envelope and core antigens of HIV, even in the presence of recombinant interleukin 2 (rIL-2). Most HIV Ab- and HIV Ab+ individuals' lymphocytes, however, could proliferate or be induced by rIL-2 to proliferate in response to lysates of Escherichia coli or Saccharomyces cerevisiae. These findings indicate selective defects in lymphocyte proliferative responses to HIV antigens before the development of AIDS in which lymphocytes are unable to proliferate in response to any antigens. These defects in cell-mediated immune responses to HIV antigens are likely to play an important role in the pathobiology of HIV infections. Although intact HIV or glycosylated gp120 envelope protein of HIV are involved in these defects, a non-glycosylated recombinant form of the HIV gp120 envelope (ENV2-3) and p25 core proteins did not inhibit antigen- or mitogen-driven lymphocyte proliferation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2703528      PMCID: PMC303807          DOI: 10.1172/JCI114001

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  31 in total

1.  Long term culture of tumour-specific cytotoxic T cells.

Authors:  S Gillis; K A Smith
Journal:  Nature       Date:  1977-07-14       Impact factor: 49.962

2.  Antibodies to human immunodeficiency virus in human sera induce cell-mediated lysis of human immunodeficiency virus-infected cells.

Authors:  E A Ojo-Amaize; P Nishanian; D E Keith; R L Houghton; D F Heitjan; J L Fahey; J V Giorgi
Journal:  J Immunol       Date:  1987-10-01       Impact factor: 5.422

3.  Retrovirus purification: method that conserves envelope glycoprotein and maximizes infectivity.

Authors:  M McGrath; O Witte; T Pincus; I L Weissman
Journal:  J Virol       Date:  1978-03       Impact factor: 5.103

4.  Proliferative and cytotoxic T cells to AIDS virus glycoproteins in chimpanzees immunized with a recombinant vaccinia virus expressing AIDS virus envelope glycoproteins.

Authors:  J M Zarling; J W Eichberg; P A Moran; J McClure; P Sridhar; S L Hu
Journal:  J Immunol       Date:  1987-08-15       Impact factor: 5.422

5.  The recovery of mice from influenza virus infection: adoptive transfer of immunity with immune T lymphocytes.

Authors:  K L Yap; G L Ada
Journal:  Scand J Immunol       Date:  1978       Impact factor: 3.487

6.  Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients.

Authors:  G V Quinnan; N Kirmani; A H Rook; J F Manischewitz; L Jackson; G Moreschi; G W Santos; R Saral; W H Burns
Journal:  N Engl J Med       Date:  1982-07-01       Impact factor: 91.245

7.  Effects of interleukin 2 and large envelope glycoprotein (gp 120) of human immunodeficiency virus (HIV) on lymphocyte proliferative responses to cytomegalovirus.

Authors:  J Krowka; D Stites; J Mills; H Hollander; T McHugh; M Busch; L Wilhelm; L Blackwood
Journal:  Clin Exp Immunol       Date:  1988-05       Impact factor: 4.330

8.  HIV-specific cytotoxic T lymphocytes in seropositive individuals.

Authors:  B D Walker; S Chakrabarti; B Moss; T J Paradis; T Flynn; A G Durno; R S Blumberg; J C Kaplan; M S Hirsch; R T Schooley
Journal:  Nature       Date:  1987 Jul 23-29       Impact factor: 49.962

9.  Human immunodeficiency virus long terminal repeat responds to T-cell activation signals.

Authors:  S E Tong-Starksen; P A Luciw; B M Peterlin
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

10.  Activation of human T lymphocyte subsets: helper and suppressor/cytotoxic T cells recognize and respond to distinct histocompatibility antigens.

Authors:  E G Engleman; C J Benike; F C Grumet; R L Evans
Journal:  J Immunol       Date:  1981-11       Impact factor: 5.422

View more
  22 in total

1.  Simian immunodeficiency virus disease course is predicted by the extent of virus replication during primary infection.

Authors:  S I Staprans; P J Dailey; A Rosenthal; C Horton; R M Grant; N Lerche; M B Feinberg
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

2.  Differential Gag-specific polyfunctional T cell maturation patterns in HIV-1 elite controllers.

Authors:  Sara Ferrando-Martínez; Joseph P Casazza; Manuel Leal; Kawthar Machmach; Ma Ángeles Muñoz-Fernández; Pompeyo Viciana; Richard A Koup; Ezequiel Ruiz-Mateos
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

Review 3.  B cell responses to HIV and the development of human monoclonal antibodies.

Authors:  J E Boyd; K James
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

Review 4.  Distinctive features of CD4+ T cell dysfunction in chronic viral infections.

Authors:  Antigoni Morou; Brent E Palmer; Daniel E Kaufmann
Journal:  Curr Opin HIV AIDS       Date:  2014-09       Impact factor: 4.283

5.  Effect of protease therapy on cytokine secretion by peripheral blood mononuclear cells (PBMC) from HIV-infected subjects.

Authors:  A D Kelleher; W A Sewell; D A Cooper
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

6.  In vitro p24 antigen-stimulated lymphocyte proliferation and beta-chemokine production in human immunodeficiency virus type 1 (HIV-1)-seropositive subjects after immunization with an inactivated gp120-depleted HIV-1 immunogen (Remune).

Authors:  R B Moss; M R Wallace; P Lanza; W Giermakowska; F C Jensen; G Theofan; C Chamberlin; S P Richieri; D J Carlo
Journal:  Clin Diagn Lab Immunol       Date:  1998-05

7.  Prolonged dominance of clonally restricted CD4(+) T cells in macaques infected with simian immunodeficiency viruses.

Authors:  Z W Chen; Y Shen; Z Kou; C Ibegbu; D Zhou; L Shen; P Morrison; C Bogle; H M McClure; A J Nahmias; P K Sehgal; N L Letvin
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

8.  Cell-mediated immunity to HIV-1 in Walter Reed stages 1-6 individuals: correlation with virus burden.

Authors:  R J Trauger; W K Giermakowska; F Ferre; P C Duffy; M R Wallace; D E Lewis; H J Beecham; K G Burnett; F C Jensen; D J Carlo
Journal:  Immunology       Date:  1993-04       Impact factor: 7.397

9.  Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides.

Authors:  Daniel E Kaufmann; Paul M Bailey; John Sidney; Bradford Wagner; Philip J Norris; Mary N Johnston; Lisa A Cosimi; Marylyn M Addo; Mathias Lichterfeld; Marcus Altfeld; Nicole Frahm; Christian Brander; Alessandro Sette; Bruce D Walker; Eric S Rosenberg
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

10.  In vitro anti-HIV-1 antibody production in subjects in different stages of HIV-1 infection.

Authors:  S Rusconi; A Riva; L Meroni; G Zehender; F Cocchi; L Scapellato; M Galli
Journal:  Clin Exp Immunol       Date:  1995-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.